Low HDL cholesterol, metformin use, and cancer risk in type 2 diabetes: the Hong Kong Diabetes Registry.
about
Metformin therapy and risk of cancer in patients with type 2 diabetes: systematic reviewMetformin and the risk of cancer: time-related biases in observational studiesDevelopment of a Web-Based Registry to Support Diabetes Care in Free Medical Clinics.Additive effects of blood glucose lowering drugs, statins and renin-angiotensin system blockers on all-site cancer risk in patients with type 2 diabetes.Validation of methods to control for immortal time bias in a pharmacoepidemiologic analysis of renin-angiotensin system inhibitors in type 2 diabetes.Metformin and cancer risk and mortality: a systematic review and meta-analysis taking into account biases and confounders.Metformin and breast cancer risk: a meta-analysis and critical literature review.Metformin and the risk of cancer in type 2 diabetes: methodological challenges and perspectivesHDL cholesterol and cancer risk among patients with type 2 diabetes.The Complexity of Vascular and Non-Vascular Complications of Diabetes: The Hong Kong Diabetes Registry.Association between metformin use and progression of monoclonal gammopathy of undetermined significance to multiple myeloma in US veterans with diabetes mellitus: a population-based retrospective cohort study.Cancer risk in diabetic patients treated with metformin: a systematic review and meta-analysis.Diabetes, insulin and cancer risk.Cancer risk associated with use of metformin and sulfonylurea in type 2 diabetes: a meta-analysisHypoglycaemia, Abnormal Lipids, and Cardiovascular Disease among Chinese with Type 2 Diabetes.Interactive effect of serum uric acid and total bilirubin for cardiovascular disease in Chinese patients with type 2 diabetes.Metformin: a new option in cancer treatment.Diabetes, cancer, and metformin: connections of metabolism and cell proliferation.Diabetes and cancer: the mechanistic implications of epidemiological analyses from the Hong Kong Diabetes Registry.The real role of prediagnostic high-density lipoprotein cholesterol and the cancer risk: a concise review.Antihyperglycaemic therapies and cancer risk.Drug-subphenotype interactions for cancer in type 2 diabetes mellitus.Metformin and cancer in type 2 diabetes: a systematic review and comprehensive bias evaluation.Uric acid, renal function and risk of hypoglycaemia in Chinese type 2 diabetes patients.Methodological challenges to control for immortal time bias in addressing drug effects in type 2 diabetes.Comment on: Suissa and Azoulay. Metformin and the risk of cancer: time-related biases in observational studies. Diabetes Care 2012;35:2665-2673Synergistic effects of low LDL cholesterol with other factors for the risk of cancer in type 2 diabetes: the Hong Kong Diabetes Registry.Evidence of subgroup-specific treatment effect in the absence of an overall effect: is there really a contradiction?Evolution of Diabetes Care in Hong Kong: From the Hong Kong Diabetes Register to JADE-PEARL Program to RAMP and PEP Program.Renin angiotensin system inhibitors may attenuate low LDL cholesterol-related cancer risk in type 2 diabetes
P2860
Q26850912-2CB1BBD8-FF83-4E00-9FD1-24B3AEC1D2F9Q26999266-3F651D89-1E8E-45CC-9D29-979E8A55C821Q33679700-EFF548F1-2A27-4DE5-9BEA-991E6D71BD64Q33715022-F8BFE18C-017B-4F46-9EBD-0A0C3C0D8E31Q33819587-C7B5F3A7-C970-4F0C-846B-37CB32CA0AB8Q34135248-4F173090-5ADC-4B8A-B09F-84616FA985DAQ34357389-2B10F54F-FCE8-4471-88DC-514C29C70A05Q34357944-6363D6D3-7784-4A22-BB61-E944DD7BF7E4Q34545361-CD0A6553-29BD-4002-ACF4-EFFDE6517DABQ34893020-A2915D33-CFC9-424F-B807-8B27D6203FEEQ35664299-08D4F5DF-B2CA-4574-AE82-CEA2D762D3F6Q35842470-CCB014E7-FF2D-4BA8-B23D-F935682C85AFQ35906970-7249933F-2202-4601-8F68-BE055E80D504Q36051510-8E221DD1-1DFB-4E11-A75F-E09CC5505448Q36173012-136C5606-B1C1-41FA-8734-283F20D275DAQ37386378-3A6D8806-CCB2-4163-A1F3-E206AA4F2EDDQ37890687-1151EE00-7AE0-43B4-95C8-1F64DAE14ED7Q37972673-42863B4D-2C13-4FCD-AEC1-52EA1CCF499BQ37982674-F87F75DE-916B-4F32-A6E2-E48E7C47EE94Q38151145-488AF876-8403-4A19-8B90-6CE41767DCB1Q38250719-37A4A88F-ACCE-469E-A9FD-034453BCE6C8Q38388443-F59C8869-3C9F-4262-B1BC-A4E94D33BF62Q38999875-51DD80D1-ED54-4032-827B-5B03D456D22CQ40493359-04E79CB7-050E-4DEB-BE5C-A3A16FC4F9DBQ41299729-99025B34-BF77-4E9F-8830-CDE0D9CAE61FQ42726741-DB29FE0A-6849-4177-B8D2-2ED0D8DFDB0BQ44107851-72325054-6B42-497B-A2A2-3CDFEF4092A3Q45196767-201200A9-1F98-4B91-9AE0-6AA2FC8D3893Q55338781-F0F5FB8F-AFB1-4934-A4F7-3CB9D89CF8A8Q58209417-60C315C8-4A28-412F-8CE0-A036DC3A4A7E
P2860
Low HDL cholesterol, metformin use, and cancer risk in type 2 diabetes: the Hong Kong Diabetes Registry.
description
2010 nî lūn-bûn
@nan
2010 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Low HDL cholesterol, metformin ...... e Hong Kong Diabetes Registry.
@ast
Low HDL cholesterol, metformin ...... e Hong Kong Diabetes Registry.
@en
Low HDL cholesterol, metformin ...... e Hong Kong Diabetes Registry.
@nl
type
label
Low HDL cholesterol, metformin ...... e Hong Kong Diabetes Registry.
@ast
Low HDL cholesterol, metformin ...... e Hong Kong Diabetes Registry.
@en
Low HDL cholesterol, metformin ...... e Hong Kong Diabetes Registry.
@nl
prefLabel
Low HDL cholesterol, metformin ...... e Hong Kong Diabetes Registry.
@ast
Low HDL cholesterol, metformin ...... e Hong Kong Diabetes Registry.
@en
Low HDL cholesterol, metformin ...... e Hong Kong Diabetes Registry.
@nl
P2093
P2860
P356
P1433
P1476
Low HDL cholesterol, metformin ...... he Hong Kong Diabetes Registry
@en
P2093
Alice P S Kong
Chun-Chung Chow
Gary T C Ko
Heung Man Lee
Linda W L Yu
Risa Ozaki
Wing Yee So
Xilin Yang
P2860
P304
P356
10.2337/DC10-1509
P407
P577
2010-10-27T00:00:00Z